Christie M. Ballantyne, MD

Director, Center for Cardiovascular Disease Prevention

Christie M. Ballantyne, MD

Director, Center for Cardiovascular Disease Prevention

Methodist DeBakey Heart Center

Chief of the Section of Cardiovascular Research

Baylor College of Medicine

Director of Atherosclerosis Laboratory

Professor of Medicine

Baylor College of Medicine

Houston, TX

Related Videos

Although the AHA Guidelines identify a 70 mg/dL threshold target for patients at high risk for recurrent ACS, do you believe this is merely a “starting point” identifying a minimal level of LDL-C goal attainment? Video

Although the AHA Guidelines identify a 70 mg/dL threshold target for patients at high risk for recurrent ACS, do you believe this is merely a “starting point” identifying a minimal level of LDL-C goal attainment?

How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended? Video

How should the 2018 AHA Guidelines for LDL-C that specify target levels for high risk patients impact our approach to selecting therapies—including PCSK9 inhibitors—that have the potential to lower LDL-C to levels far lower than those recommended?

From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction? Video

From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction?

A confluence of events has reshaped the accessibility, evidence basis, and actionability profile for PCSK9 inhibitors. As an atherosclerosis specialist, how have these developments changed the equation and shaped your approach to CV risk reduction? Video

A confluence of events has reshaped the accessibility, evidence basis, and actionability profile for PCSK9 inhibitors. As an atherosclerosis specialist, how have these developments changed the equation and shaped your approach to CV risk reduction?